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Community views on factors influencing medicines resource allocation: A cross sectional 1 
survey of 3080 adults in Australia 2 
Abstract  3 
Objectives:  To determine Australian community views on factors that influence distribution of 4 
health spending in relation to medicines.  5 
Methods: Cross-sectional web-based survey of 3080 adults aged 18 years or older.   Participants 6 
were asked to rank, in order of importance, 12 criteria according to which medicines funding 7 
decisions might be made.  8 
Results:  1213 (39.4%) of respondents considered disease severity to be the most important 9 
prioritisation criterion for funding a new medicine. This was followed by medicines treating a disease 10 
affecting children (13.2%), and medicines for cancer patients (9.1%). Medicines targeting a disease 11 
for which there is no alternative treatment available received highest priority from 8.6 % of 12 
respondents. The remaining 8 prioritisation criteria were each assigned a top ranking by respondents 13 
ranging from 6.6% to 1.7%. Medicines targeting a disease for which there is no alternative treatment 14 
available were ranked least important by 7.7% of respondents compared to 2.4%, 1.9% and 1.0% for 15 
medicines treating severe diseases, diseases affecting children and cancer, respectively. ‘End-of-life 16 
treatments’ and ‘rare disease therapies’ received the least number of highest priority rankings (2.0% 17 
and 1.7% respectively).  18 
Conclusions:  19 
These results provide useful information about public preferences for government spending on 20 
prescribed medicines. Understanding of public preferences on funding of new medicines will help 21 
the PBAC/government determine circumstances where greater emphasis on equity is required and 22 
help inform medicines funding policy that best meets the needs of the Australian population. 23 
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What is known about this topic? There is increased recognition of the importance of taking into 24 
account public preferences in the heath technology assessment (HTA) decision-making process.   25 
What does this paper add?  The Australian public view the severity of disease to be the most 26 
important funding prioritisation criterion for medicines, followed by medicines used to treat children 27 
or to treat cancer.   28 
What are the implications for practitioners? The general public are capable of giving opinions on 29 
distributional preferences.  This information can help inform medicines funding policy and ensure 30 
that it is consistent with the values of the Australian population.  31 
Introduction 32 
In Australia, the Pharmaceutical Benefits Advisory Committee (PBAC) is responsible for advising the 33 
government as to which medicines should be subsidised on the Pharmaceutical Benefits Scheme 34 
(PBS). In fulfilling this role, the PBAC is the steward of a large sum of public money: for the 12 35 
months ending 30 June 2015, for example, total PBS spending amounted to $9.07 billion 1.  36 
The PBAC makes its recommendations primarily on the basis of evidence of clinical effectiveness, 37 
safety and cost effectiveness derived from clinical trials and population-based observational studies. 38 
The PBAC also takes into account other factors, such as equity, in its consideration of what does, or 39 
does not, constitute “value for money”. In this context, the term “equity” refers to access to PBS 40 
listed drugs in a manner that takes into account the distribution of benefits and potential harms 41 
based on factors such as prognosis, disease severity, age, distributional effect, context (eg. 42 
emergency or prevention),  socioeconomic and geographical status and other issues not typically 43 
considered as part of quality of life measurements2.  44 
Previous analyses of PBAC recommendations demonstrated that the PBAC has been broadly 45 
consistent in its use of economic efficiency as a key criterion for decision making 3, 4. The probability 46 
of a positive recommendation does increase with lower incremental cost effectiveness ratios but 47 
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there is no evidence of a fixed threshold for the value of a life year or a quality adjusted life year 48 
(QALY)4. Importantly, the PBAC has been found to actualise equity considerations by accepting a 49 
higher incremental cost effectiveness ratio (ICER) for medicines addressing a high unmet clinical 50 
need 5-7 and/or greater uncertainty in the available clinical evidence for rare diseases8. 51 
Further, the PBAC in its deliberation may consider the ‘Rule of Rescue’ (RoR). The consideration and 52 
application of RoR allows the PBAC to potentially reverse a decision not to recommend listing on the 53 
because of its consideration of comparative cost-effectiveness (and any other relevant factors). 54 
However, evidence (based on the published Public Summary Documents (PSDs) for past PBAC 55 
recommendations) indicates that the RoR has been applied infrequently by the PBAC and that there 56 
were few documented examples where application of the RoR  has led to a positive PBAC 57 
recommendation9.  PBAC consideration of the RoR requires the following four factors to be met: (1) 58 
no alternatives exist in Australia (2) the medical condition is severe, progressive and expected to 59 
lead to premature death (3) the medical condition applies to only a very small number of patients 60 
and (4) the proposed medicine provides a worthwhile clinical improvement sufficient to qualify as a 61 
rescue from the medical condition 2. However, the relative influence/weight of the RoR factors is not 62 
quantitatively pre-defined. Importantly, the RoR as with other relevant factors supplements, rather 63 
than substitutes for evidence based consideration of cost-effectiveness 2.  64 
The PBAC also provides advice on the inclusion of medicines on the Life Savings Drugs program 65 
(LSDP) 9. The LSDP sits outside the PBS to provide an alternate funding arrangement for access to 66 
medicines that are not eligible for funding under the PBS due to unacceptable cost effectiveness. 67 
While those making submissions to the PBAC occasionally include population survey data on 68 
community preferences, assessments of equity are most commonly based on assumptions about 69 
community priorities.  Given the central role that the general public has in funding publicly 70 
subsidised health technologies through taxes, and as beneficiaries of these technologies, it is 71 
increasingly recognised that this is inadequate, and that more information is needed about public 72 
preferences when making decisions about the funding of new medicines10-12.   73 
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Around the world, government agencies responsible for the selection and reimbursement of 74 
prescribed medicines and other health technologies are increasingly concerned with how best to 75 
incorporate community preferences into their decision making13, 14. In Australia, the PBAC currently 76 
considers patients and the public views through consumer representation on the Committee, via an 77 
online consumer input process, as well as through consumer hearings convened by the PBAC for 78 
selected submissions. Recent examples of such hearings include those for lymphoma (brentuximab 79 
vedotin, bendamustine, idelalisib and obinutuzumab), which were considered at the March 2015 80 
PBAC meeting 15, and for ovarian cancer and Morquio A syndrome (olarparib and elosulfase alfa 81 
respectively) which were considered at the March 2016 PBAC meeting 16.  82 
Another important approach to eliciting consumer preferences, which supplements more direct 83 
forms of consumer engagement, is to conduct surveys of representative samples of the community. 84 
These have been used previously to support policy concerning the funding of cancer drugs in the 85 
UK17, to assess the preferences for the funding of orphan drugs18 and to understand public 86 
agreement with policies aimed to facilitate access to life-extending drugs used at the end of 87 
patients’ lives19.  To date, however, no representative community survey has explored how members 88 
of the Australian community rank various criteria according to their importance to funding decisions 89 
for prescribed medicines.  We therefore conducted an on-line survey of 3080 Australians aged 18 90 
years or older in order to measure community preferences for the distribution of the benefits and 91 
costs of PBS listed drugs.  92 
Methods 93 
We undertook a cross sectional web based survey of 3080 adult Australians aged 18 years or older. 94 
This paper focuses on the findings from the ranking exercise conducted as part of the present study.  95 
SSI, a market research company with a large online panel (~ 409,000 registered members) was used 96 
to recruit survey participants. Recruitment was controlled by gender, age and geographical area 97 
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(state of residence) in order to ensure that the sample was representative of the general adult 98 
Australian population. Participants were compensated for their time and received ‘reward points’ 99 
averaging $1.40 from the panel provider. Selection of the 12 prioritisation criteria was informed by 100 
both the published literature and criteria currently used by the PBAC when assessing new medicines 101 
for public subsidy. 5,6,7,8, 9,10   The 12 prioritisation criteria, were: (1) severity of disease (2) availability 102 
of alternative medicine (3) significant innovation (4) carer burden (5) disadvantaged populations (6) 103 
children (7) end-of-life treatments (8) cancer treatments (9) rare disease therapies (10) cost to the 104 
PBS and savings to patient (11) medicines that help patients return to work (12) Life-style related 105 
diseases and individual responsibility. 106 
The survey asked respondents which criteria they believed were the most important in healthcare 107 
spending and resource allocation. Respondents were asked to rank the 12 prioritisation criteria from 108 
one to 12, with one being the most important criterion. The survey was pilot tested with 111 109 
participants in August 2015. An additional question regarding the state of residence was added after 110 
pilot testing.  The full survey was administered during October 2015 and closed when our target of 111 
3000 complete responses was achieved. Socio-demographic data were collected to test associations 112 
between respondents’ views on the prioritisation criteria and demographic characteristics. 113 
Ethics approval 114 
This study was approved by Human Ethics Research Committee at Sydney University (protocol 115 
number: 2014/906). 116 
Statistical analysis 117 
Descriptive statistics were used to summarize demographic variables. Empirical studies have found 118 
that willingness to pay and funding preferences are influenced by respondents’ personal 119 
circumstances such as age, income, health status, household composition17, 20. Multinomial logistic 120 
regression modelling   was used to assess whether gender, age, marital status, education , health 121 
status, cancer history, country of birth, private health insurance, employment status, household 122 
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income, and dependent children   were associated with the top ranking  of the 12 prioritisation 123 
criteria. The model included all explanatory variables listed.  124 
Results 125 
A total of 3080 adult members of the general public in Australia completed the on-line survey.  The 126 
3080 respondents broadly reflected the Australian population in terms of age, gender and 127 
geographical area (Table 1). 39.4% of respondents considered disease severity to be the most 128 
important prioritisation criterion (Table 2). This was followed by medicines for diseases affecting 129 
children (13.2%). Cancer medicines came third and were ranked most important by 9.1% of 130 
respondents, while medicines targeting a disease for which there is no alternative treatment 131 
available received highest priority from 8.6 % of respondents. The remaining 8 prioritisation criteria 132 
were each assigned a top ranking by respondents ranging from 6.6% to 1.7%.  133 
The four prioritisation criteria that were assigned the highest priority, also received the largest 134 
number of top 3 rankings:  disease severity (n= 1966, 21.3%), medicines for children (n= 1260, 135 
13.6%), cancer medicines (n= 1112, 12.0%), and medicines targeting a disease for which no other 136 
medicine is available (n= 957, 10.4%).  137 
Medicines targeting a disease for which there is no alternative treatment available were ranked least 138 
important (i.e. with a respondent’s assigned rank order of 12) by 7.7% of respondents compared to 139 
2.4%, 1.9% and 1.0% for medicines treating severe/life threatening diseases, treating a disease 140 
affecting children and medicines for cancer patients, respectively.  141 
‘End-of-life treatments’ and ‘rare disease therapies’ received the least number of highest priority 142 
rankings (2.0% and 1.7% respectively).  143 
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Relationship between respondent characteristics and prioritisation 144 
preferences 145 
 Country of birth (p= 0.04), employment status (p= 0.04) and having dependent children (p= 0.0001) 146 
were associated with funding preferences (see Supplementary file). Respondents who were born 147 
overseas were significantly more likely to assign a top priority to medicines that help patients return 148 
to work (OR= 1.57, 95% CI= 1.06 to 2.32, p= 0.02), and to medicines targeting life style unrelated 149 
diseases (OR= 1.57, 95% CI= 1.01 to 2.42, p= 0.04) than to prioritise disease severity, compared to 150 
those born in Australia. Respondents with dependent children were significantly more likely to 151 
assign a top ranking to medicines targeting diseases affecting children (OR= 2.04, 95% CI= 1.52 to 152 
2.78, p<0.0001), and to cancer medicines (OR= 1.45, 95% CI= 1.01 to 2.04, p= 0.04). Respondents 153 
who are in part time employment were significantly less likely to assign a top finding priority to 154 
medicines targeting rare diseases than those working full time (OR= 0.19, 95% CI= 0.05 to 0.66, p= 155 
0.01). Compared to respondents who were in full time employment, respondents who were neither 156 
in employment nor unemployed (i.e. ‘other’ category, for example those who were looking after a 157 
home or studying full time) were significantly more likely to assign a top ranking to medicines 158 
targeting diseases that affect patients who are not financially well off (OR= 1.72, 95% CI= 1.02 to 159 
2.87, p= 0.04). Further, these respondents were significantly less likely to allocate the highest 160 
funding priority to medicines targeting life style unrelated diseases (OR= 0.15, 95% CI= 0.03 to 0.63, 161 
p= 0.01) compared with those in full time employment.  162 
There was also some evidence that health status (P= 0.06) and private health insurance (P= 0.06) 163 
were associated with funding preferences. Compared with respondents rating themselves as in very 164 
good health, respondents who rated themselves as in good, average, or poor/very poor health were 165 
significantly more likely to assign a top ranking to medicines targeting diseases that affect patients 166 
who are not financially well off (OR= 1.90, 95% CI= 1.13 to 3.20, p= 0.02; OR= 2.33, 95% CI= 1.35 to 167 
4.01, p= 0.002; OR= 2.40, 95% CI= 1.20 to 4.79, p=  0.01 respectively), and to medicines that cost the 168 
government more and thereby save patients more in out-of-pocket costs (OR= 2.25, 95% CI= 1.19 to 169 
8 
 
4.26, p= 0.01; OR= 2.18, 95% CI= 1.11 to 4.28, p= 0.02; OR= 3.12, 95% CI= 1.39 to 7.02, p= 0.006 170 
respectively).   Respondents who do not have private health insurance were significantly more likely 171 
to allocate the highest funding priority to medicines that cost the government more, thereby saving 172 
patients more in out-of-pocket costs compared to those with private health insurance (OR= 1.58, 173 
95% CI= 1.07 to 2.31, p= 0.02). , 174 
Discussion 175 
The results of our study give a clear picture of public preferences regarding resource allocation for 176 
medicines.  The targeting of severe or life threatening diseases is clearly and by far the most 177 
important prioritisation criterion , followed by medicines  targeting  diseases affecting children, 178 
cancer medicines and medicines targeting diseases for which no  treatment alternative is available. 179 
Whilst the first three top ranking prioritisation criteria were assigned a least important ranking by a 180 
small proportion of respondents (1 to 2.4%). Medicines targeting a disease for which no alternative 181 
treatment exists were ranked most and least important by a similar proportion of respondents (8.6% 182 
and 7.7%, respectively). One possible explanation for this variation is that societal opinion on the use 183 
of this as a prioritisation criterion for new medicines funding may be divided and ‘polarised’.  184 
Further, findings from this study resonate with previous studies11, 17, 19, 21, 22,  which have shown that 185 
members of the general public give higher priority to medicines used for the treatment of severe 186 
illness and for those with no available alternatives.  The finding of support for prioritising anti-cancer 187 
medicines is also generally consistent with existing evidence23, 24, and could explain the current focus 188 
both in Australia and internationally on achieving timely access to such treatments25. However, as 189 
cancer medicines are the only disease specific medicines explored in this study, this finding should 190 
be interpreted with caution. We found no compelling evidence for prioritising end-of-life 191 
treatments. This is  consistent with a study by Linley et al17, which examined the views of the UK 192 
general public about the current and proposed medicines prioritisation criteria used by the UK 193 
National Institute of Health and Care Excellence (NICE) and government.  194 
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Our study suggests that rare disease therapies per se are not a strong driver for public funding 195 
preferences. Although this is consistent with other research17, 18, it is  nonetheless a somewhat 196 
surprising finding given that rarity of disease is one of the four criteria that form the basis of the ‘rule 197 
of rescue’ (RoR) PBAC claim2. A RoR applies in exceptional circumstances for drugs that provide a 198 
worthwhile benefit for a severe and rare condition for which there is no alternative treatment2, 9, 26. 199 
The results of our study suggest that the use of rarity of the disease as an inclusion criterion for LSDP 200 
or as a basis for a RoR claim does not appear to be supported by the Australian public. One possible 201 
interpretation of this result is that rarity is not a shared prioritisation criterion between the general 202 
public and the PBAC. Given that rarity of the disease is linked to the total number of eligible patients 203 
and cost for funding a medicine, it is, and may need to remain, an important prioritisation criterion 204 
from the PBAC/government perspective, especially for high cost medicines.  205 
An important strength of our study is that it included a large, broadly representative sample of 3080 206 
adult Australians. However, due to the design of our study, non-completion rates and details of non-207 
responders were unavailable for analysis or assessment for potential non-responder bias. Another 208 
potential limitation relates to framing effects. It has been found that the choice of wording in 209 
surveys is very important27. The results for the prioritisation criterion relating to life-style unrelated 210 
diseases appear to be somewhat surprising, with the largest proportion of respondents ranking this 211 
criterion last. It is possible that respondents’ preferences may have been confounded by the 212 
labelling choice used in the survey. Despite these limitations, our study has important implications 213 
for health policy development with respect to the funding of new medicines in Australia.  214 
Further, our research shows that respondents’ funding preferences for access to new medicines are 215 
influenced by their personal characteristics and circumstances. Therefore, if the general public’s 216 
views and preferences are to be included in the PBAC decision making process, a representative 217 
sample is required.    218 
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 In summary, the findings of this study provide assurance that the Australian public support some of 219 
the currently used prioritisation criteria. However, quantification of criteria weights and equity 220 
issues relative to other factors will require further research in order to provide guidance to the PBAC 221 
on the cardinality of equity preferences and quantification of ICER increase to account for the 222 
specific equity issues/criteria identified.   223 
Conclusions 224 
The reimbursement  of prescribed medicines should reflect both evidence of safety and 225 
effectiveness, and  social values28.  As such, it is important to understand societal views and 226 
preferences for the distribution of healthcare spending. Results of this study provide useful 227 
information on public preferences related to the equity aspects of government spending on 228 
prescribed medicines in Australia. Understanding of public preferences on funding of new medicines 229 
could help the PBAC/government determine circumstances in which greater emphasis on equity is 230 
required, and how equity might be defined and achieved in a manner that is congruent with the 231 
values of the Australian population. To ensure that public preferences are reflected in the PBAC’s 232 
assessments and recommendations, there is a need for further research to determine the best way 233 
to incorporate these preferences into PBAC decision making processes. This will, in turn, improve 234 
alignment between government and societal preferences for funding of new medicines29, 30.   235 
11 
 





Gender    
   Male  1502  48.8 48.9 
   Female  1578 51.2 51.1 
Age (years)    
   18-24  374 12.1 12.2 
   25-34  542 17.6 18.0 
   35-44  596 19.4 18.5 
   45-54  553 18.0 17.9 
   55-64  481 15.6 15.2 
   65+  534 17.3 18.2 
Marital status    
   Married/de facto  1832 59.5  
   Separated/divorced/widowed  406 13.2  
   Never married  842 27.3  
Education    
Never attended school/ primary/ some high 
school/  preferred not to answer 
444 14.4  
   Completed high school  627 20.4  
   University, TAFE etc.  2009 65.2  
Cancer history      
Cancer history with death 1175 38.1  
Cancer history with no death/death unknown 489 15.9  
No cancer history 1376 44.7  
Prefer not to answer 40 1.3  
General health    
   Very good  544 17.7  
   Good  1481 48.1  
   Average  842 27.3  
   Poor/ very poor  213 6.9  
Country of birth    
   Australia  2285 74.2  
   Overseas  795 25.8  
Private health insurance    
   Yes  1814 59  
   No  1266 41  
Employment status    
Working full time   1082 35.1  
Working part time  622 20.2  
Currently not working, but looking for work 376 12.2  
Retired  669 21.7  
Other  331 10.7  
Household annual income    
  $0 to 20,000  249 8.1  
  $20,001- 40,000  610 19.8  
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1 The pilot survey did not include this demographic question (n= 111) 237 
2 Australia demographics (gender, age and state of residence) are for persons aged 18 years and over, sourced 238 
from the TableBuilder available from the Australian Bureau of Statistics based on the 2011 Census data. 239 
(http://www.abs.gov.au/websitedbs/censushome.nsf/home/tablebuilder?opendocument&navpos=240).  240 
Abbreviation: TAFE= Technical and Further Education  241 
  $40,001 to 80,000  863 28.0  
  $80,001 and over 1008 32.7  
   Prefer not to answer  350 11.4  
Personal annual income    
   $0 to 20,000  754 24.5  
   $20,001- 40,000  711 23.1  
   $40,001 to 80,000  792 25.7  
   $80,001 to 180,000  422 13.7  
   $180,001 and over  47 1.5  
   Prefer not to answer 354 11.5  
Household composition    
With financially dependent children 927 30.1  
Without financially dependent children 2153 69.9  
State    
Australian Capital Territory 47 1.5 1.7 
New South Wales 985 32.0 32.2 
Northern Territory 10 0.3 0.9 
Queensland 587 19.1 19.9 
South Australia 236 7.7 7.6 
Tasmania 70 2.3 2.3 
Victoria 745 24.2 25.1 
Western Australia 289 9.4 10.4 
Unknown1 111 3.6 - 
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Table 2:  Number of times a prioritisation criterion was assigned the top priority, lowest priority 242 
(i.e. with a ranking order of 1 and 12 respectively), and top 3 rankings by respondents  243 












Severity of disease 
Preference for funding should be given to new medicines 
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Availability of alternative treatment options 
Preference for funding should be given to new medicines 
that target diseases for which no other treatments are 








Preference for funding should be given to new medicines 
targeting diseases that typically affect disadvantaged 







Cost to the PBS and savings to patient  
Preference for funding should be given to new medicines 
that cost the government more and thereby save patients 







Medicines that help patients return to work  
Preference for funding should be given to new medicines 








Preference for funding should be given to new medicines 
targeting diseases that, if untreated, cause patients to be 







Life style related diseases and individual responsibility 
Preference for funding should be given to new medicines 
targeting diseases that are not considered to be a life-style 
related disease i.e. diseases that could not be avoided 








Preference for funding should be given to new medicines 








Preference for funding should be given to new medicines 
that prolong life –even for a few months- at the end of life 








Preference for funding should be given to new medicines 
targeting rare diseases i.e. diseases affecting less than 2000 
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